Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

The data showed that both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

Novavax (NVAX) stock jumped on Wednesday after the vaccine maker released results from a Phase 3 clinical trial of its COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine. The initial ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Results showed that the CIC and flu vaccines generated “robust immune responses” across three flu strains (H1N1, H3N2 and B) ...

US biotech Novavax (Nasdaq: NVAX) has reported that its experimental combination COVID-19 and influenza vaccine generated ...

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ETCompany ParticipantsJames Patrick Kelly ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...